331 related articles for article (PubMed ID: 32015176)
1. Intermediate flortaucipir uptake is associated with Aβ-PET and CSF tau in asymptomatic adults.
McSweeney M; Pichet Binette A; Meyer PF; Gonneaud J; Bedetti C; Ozlen H; Labonté A; Rosa-Neto P; Breitner J; Poirier J; Villeneuve S;
Neurology; 2020 Mar; 94(11):e1190-e1200. PubMed ID: 32015176
[TBL] [Abstract][Full Text] [Related]
2. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.
Buckley RF; Hanseeuw B; Schultz AP; Vannini P; Aghjayan SL; Properzi MJ; Jackson JD; Mormino EC; Rentz DM; Sperling RA; Johnson KA; Amariglio RE
JAMA Neurol; 2017 Dec; 74(12):1455-1463. PubMed ID: 28973551
[TBL] [Abstract][Full Text] [Related]
3. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
[TBL] [Abstract][Full Text] [Related]
4. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
5. Inferior temporal tau is associated with accelerated prospective cortical thinning in clinically normal older adults.
Scott MR; Hampton OL; Buckley RF; Chhatwal JP; Hanseeuw BJ; Jacobs HI; Properzi MJ; Sanchez JS; Johnson KA; Sperling RA; Schultz AP
Neuroimage; 2020 Oct; 220():116991. PubMed ID: 32512123
[TBL] [Abstract][Full Text] [Related]
6. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
[TBL] [Abstract][Full Text] [Related]
7. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
8. Tau accumulation in autosomal dominant Alzheimer's disease: a longitudinal [
O'Connor A; Cash DM; Poole T; Markiewicz PJ; Fraser MR; Malone IB; Jiao J; Weston PSJ; Flores S; Hornbeck R; McDade E; Schöll M; Gordon BA; Bateman RJ; Benzinger TLS; Fox NC
Alzheimers Res Ther; 2023 May; 15(1):99. PubMed ID: 37231491
[TBL] [Abstract][Full Text] [Related]
9. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
10. Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment.
Knopman DS; Lundt ES; Therneau TM; Albertson SM; Gunter JL; Senjem ML; Schwarz CG; Mielke MM; Machulda MM; Boeve BF; Jones DT; Graff-Radford J; Vemuri P; Kantarci K; Lowe VJ; Petersen RC; Jack CR;
JAMA Neurol; 2021 Feb; 78(2):217-228. PubMed ID: 33074304
[TBL] [Abstract][Full Text] [Related]
11. Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts.
Provost K; Iaccarino L; Soleimani-Meigooni DN; Baker S; Edwards L; Eichenlaub U; Hansson O; Jagust W; Janabi M; La Joie R; Lesman-Segev O; Mellinger TJ; Miller BL; Ossenkoppele R; Pham J; Smith R; Sonni I; Strom A; Mattsson-Carlgren N; Rabinovici GD;
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(7):2259-2271. PubMed ID: 33398408
[TBL] [Abstract][Full Text] [Related]
12. Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.
Quiroz YT; Sperling RA; Norton DJ; Baena A; Arboleda-Velasquez JF; Cosio D; Schultz A; Lapoint M; Guzman-Velez E; Miller JB; Kim LA; Chen K; Tariot PN; Lopera F; Reiman EM; Johnson KA
JAMA Neurol; 2018 May; 75(5):548-556. PubMed ID: 29435558
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity-Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration.
Ghirelli A; Tosakulwong N; Weigand SD; Clark HM; Ali F; Botha H; Duffy JR; Utianski RL; Buciuc M; Murray ME; Labuzan SA; Spychalla AJ; Pham NTT; Schwarz CG; Senjem ML; Machulda MM; Baker M; Rademakers R; Filippi M; Jack CR; Lowe VJ; Parisi JE; Dickson DW; Josephs KA; Whitwell JL
Ann Neurol; 2020 Nov; 88(5):1009-1022. PubMed ID: 32869362
[TBL] [Abstract][Full Text] [Related]
14. Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease.
Ossenkoppele R; Smith R; Ohlsson T; Strandberg O; Mattsson N; Insel PS; Palmqvist S; Hansson O
Neurology; 2019 Feb; 92(6):e601-e612. PubMed ID: 30626656
[TBL] [Abstract][Full Text] [Related]
15. Spatial Extent of Amyloid-β Levels and Associations With Tau-PET and Cognition.
Ozlen H; Pichet Binette A; Köbe T; Meyer PF; Gonneaud J; St-Onge F; Provost K; Soucy JP; Rosa-Neto P; Breitner J; Poirier J; Villeneuve S;
JAMA Neurol; 2022 Oct; 79(10):1025-1035. PubMed ID: 35994280
[TBL] [Abstract][Full Text] [Related]
16. Regional [
Wolters EE; Ossenkoppele R; Verfaillie SCJ; Coomans EM; Timmers T; Visser D; Tuncel H; Golla SSV; Windhorst AD; Boellaard R; van der Flier WM; Teunissen CE; Scheltens P; van Berckel BNM
Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2866-2878. PubMed ID: 32291510
[TBL] [Abstract][Full Text] [Related]
17. Early neuroinflammation is associated with lower amyloid and tau levels in cognitively normal older adults.
Albrecht DS; Sagare A; Pachicano M; Sweeney MD; Toga A; Zlokovic B; Chui H; Joe E; Schneider L; Morris JC; Benzinger T; Pa J
Brain Behav Immun; 2021 May; 94():299-307. PubMed ID: 33486003
[TBL] [Abstract][Full Text] [Related]
18. Partial volume correction in longitudinal tau PET studies: is it really needed?
Costoya-Sánchez A; Moscoso A; Sobrino T; Ruibal Á; Grothe MJ; Schöll M; Silva-Rodríguez J; Aguiar P;
Neuroimage; 2024 Apr; 289():120537. PubMed ID: 38367651
[TBL] [Abstract][Full Text] [Related]
19. Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18.
Devous MD; Joshi AD; Navitsky M; Southekal S; Pontecorvo MJ; Shen H; Lu M; Shankle WR; Seibyl JP; Marek K; Mintun MA
J Nucl Med; 2018 Jun; 59(6):937-943. PubMed ID: 29284675
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.
Leuzy A; Smith R; Ossenkoppele R; Santillo A; Borroni E; Klein G; Ohlsson T; Jögi J; Palmqvist S; Mattsson-Carlgren N; Strandberg O; Stomrud E; Hansson O
JAMA Neurol; 2020 Aug; 77(8):955-965. PubMed ID: 32391858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
